CLAIMS

1. Use of an allogeneic population of culture expanded mesenchymal precursor cells (MPC)s comprising an oncolytic herpes simplex virus (HSV) or an oncolytic adenovirus in the manufacture of a medicament for treating a cancer in a subject, in which the MPCs have been culture expanded from a population of STRO-1+ MPCs, in which the cancer is selected from the group consisting of: lung cancer, pancreatic cancer, colorectal cancer, liver cancer, cervical cancer, prostate cancer, osteosarcoma, breast cancer and melanoma.

2. Use according to Claim 1, in which the MPCs express one or more of the markers selected from the group consisting of α1, α2, α3, α4 and α5, αv, β1 and β3.

3. Use according to Claim 1 or 2, in which the oncolytic HSV or the oncolytic adenovirus comprises a tumour specific promoter and/or a capsid protein that binds a tumour-specific cell surface molecule.

4. Use according to Claim 3, in which the tumour specific promoter is a survivin promoter, COX-2 promoter, PSA promoter, CXCR4 promoter, STAT3 promoter, hTERT promoter, AFP promoter, CCKAR promoter, CEA promoter, erbB2 promoter, E2F1 promoter, HE4 promoter, LP promoter, MUC-1 promoter, TRP1 promoter, or a Tyr promoter.

5. Use according to any preceding claim, in which the oncolytic HSV or oncolytic adenovirus comprises a capsid protein that binds to a tumour specific cell surface molecule for transductionally targeting a tumour cell.

6. Use according to Claim 5, in which the tumour specific cell surface molecule is selected from the group consisting of an integrin, an EGF receptor family member, a proteoglycan, a disialoganglioside, B7-H3, cancer antigen 125 (CA-125), epithelial cell adhesion molecule (EpCAM), vascular endothelial growth factor receptor 1 , vascular endothelial growth factor receptor 2, carcinoembryonic antigen (CEA), a tumour associated glycoprotein, cluster of differentiation 19 (CD19), CD20, CD22, CD30, CD33, CD40, CD44, CD52, CD74, CD152, mucin 1 (MUC1), a tumour necrosis factor receptor, an insulin-like growth factor receptor, folate receptor a, transmembrane glycoprotein NMB, a C-C chemokine receptor, prostate specific membrane antigen (PSMA), recepteur d'origine nantais (RON) receptor, and cytotoxic T-lymphocyte antigen 4.

7. Use according to any preceding claim, in which the oncolytic virus is the oncolytic HSV.

8. Use according to any of Claims 1 to 6, in which the oncolytic virus is the oncolytic adenovirus.

9. Use according to Claim 8, in which the oncolytic adenovirus is a conditionally replicating adenovirus (CRAd).

10. Use according to any preceding claim, in which the mesenchymal lineage precursor or stem cells are STRO-1^{bri}.

11. Use according to any preceding claim, in which the MPCs were derived from induced pluripotent stem (iPS) cells.

12. Use according to any preceding claim, in which the cancer is a syncytial cancer.